Table of Content

1. Key Insights

2. Adalimumab Biosimilars: Snapshot

3. Executive Summary
3.1. Overview
3.2. The Basics of Biologics.
3.3. Biosimilars are not the Same as Generic Drugs
3.4. Economics of Biosimilars – the Promise of Lower Prices, but at What Cost?
3.5. What Patients Need to Know About Biosimilars

4. Regulatory Outlook For Biosimilars
4.1. North America
4.1.1. US
4.1.2. Canada
4.2. Europe
4.3. Asia Pacific
4.3.1. China
4.3.2. India
4.3.3. Japan
4.3.4. South Korea
4.3.5. Australia
4.4. Rest Of The World
4.4.1. Brazil
4.4.2. Mexico
4.4.3. Argentina
4.4.4. Saudi Arabia
*More Countries would be added in the final report

5. Adalimumab (Reference Product: Humira)
5.1. Drug Profile
5.2. Product Overview
5.3. Regulatory Approvals and Launch
5.4. Indications
5.5. Mechanism of Action
5.6. Dosage and Administration
5.7. Dosage and Strengths
5.8. Dose Modification
5.9. Route of Synthesis
5.10. Pharmacology
5.11. Pharmacodynamics
5.12. Pharmacokinetics
5.13. Adverse Reactions
5.14. Product Snapshot
5.15. Development Milestones

6. Research and Development
6.1. Clinical Trials Information
6.2. Safety and Efficacy

7. Humira Biosimilar: Emerging Opportunities

8. Adalimumab: Biosimilars Assessment
8.1. Assessment by Product Type
8.2. Assessment by Route of Administration
8.3. Assessment by Molecule type
8.4. Sales Assessment

9. Adalimumab Biosimilars Profiles: By Company
9.1.1. Pfizer
9.1.1.1. Abrilada: Pfizer
9.1.1.1.1. Product Information
9.1.1.1.2. Research and Development
9.1.1.1.3. Other Development Activities
9.1.1.1.4. General Description Table
9.1.2. Innovent Biologics
9.1.2.1. IBI-303: Innovent Biologics
9.1.2.1.1. Product Information
9.1.2.1.2. Research and Development
9.1.2.1.3. Other Development Activities
9.1.2.1.4. General Description Table
9.1.3. Celltrion
9.1.3.1. CT-P17: Celltrion
9.1.3.1.1. Product Information
9.1.3.1.2. Research and Development
9.1.3.1.3. Other Development Activities
9.1.3.1.4. General Description Table
9.1.4. Shanghai Henlius Biotech
9.1.4.1. HLX 03: Shanghai Henlius Biotech
9.1.4.1.1. Product Information
9.1.4.1.2. Research and Development
9.1.4.1.3. Other Development Activities
9.1.4.1.4. General Description Table
9.1.5. Sandoz
9.1.5.1. Hyrimoz: Sandoz
9.1.5.1.1. Product Information
9.1.5.1.2. Research and Development
9.1.5.1.3. Other Development Activities
9.1.5.1.4. General Description Table
9.1.5.2. Halimatoz: Sandoz
9.1.5.2.1. Product Information
9.1.5.2.2. Research and Development
9.1.5.2.3. Other Development Activities
9.1.5.2.4. General Description Table
*More Companies and products would be added in the final report

10. Adalimumab Biosimilars: Comparative Landscape: By Company

11. Adalimumab Biosimilars: Competitive Landscape
11.1.1. Overview
11.1.2. Market Share Analysis
11.1.3. Competitive Scenario
11.1.3.1. Product Launches and approval
11.1.3.2. Partnerships, Collaborations and Agreements
11.1.3.3. Acquisitions
11.1.3.4. Expansions
11.1.3.5. Patent Expiration of Biologics
*More information would be added in the final report

12. Market Drivers

13. Market Barriers

14. SWOT Analysis

15. Appendix
15.1. Research Methodology
15.1.1. Coverage
15.1.2. Secondary Research

16. Bibliography

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight



List of Figures


Figure 1 Total Products for Adalimumab
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products


List of Tables


Table 1 Total Products for Adalimumab
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products